Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial

Intravenous Vitamin ◽

Decision letter for "Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: an international multicenter randomized trial"

10.1002/hon.2693/v3/decision1 ◽

2019 ◽

Keyword(s):

Randomized Trial ◽

Review for "Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: an international multicenter randomized trial"

10.1002/hon.2693/v1/review2 ◽

2019 ◽

Keyword(s):

Randomized Trial ◽

Two vs one forward view examination of right colon on adenoma detection: an international multicenter randomized trial

Clinical Gastroenterology and Hepatology ◽

10.1016/j.cgh.2020.10.014 ◽

2020 ◽

Author(s):

Raymond S.Y. Tang ◽

Jonathan W.J. Lee ◽

Li-Chun Chang ◽

David E.H. Ong ◽

Han-Mo Chiu ◽

...

Keyword(s):

Randomized Trial ◽

Right Colon ◽

Adenoma Detection ◽

Author response for "Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: an international multicenter randomized trial"

10.1002/hon.2693/v2/response1 ◽

2019 ◽

Author(s):

Irina V. Poddubnaya ◽

Sergey M. Alekseev ◽

Kamil D. Kaplanov ◽

Les M. Lukavetskyy ◽

Grigoriy B. Rekhtman ◽

...

Keyword(s):

Randomized Trial ◽

Author Response ◽

Decision letter for "Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: an international multicenter randomized trial"

10.1002/hon.2693/v1/decision1 ◽

2019 ◽

Keyword(s):

Randomized Trial ◽

Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: An international multicenter randomized trial

Hematological Oncology ◽

10.1002/hon.2693 ◽

2020 ◽

Vol 38 (1) ◽

pp. 67-73 ◽

Cited By ~ 2

Author(s):

Irina V. Poddubnaya ◽

Sergey M. Alekseev ◽

Kamil D. Kaplanov ◽

Les M. Lukavetskyy ◽

Grigoriy B. Rekhtman ◽

...

Keyword(s):

Randomized Trial ◽

Author response for "Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: an international multicenter randomized trial"

10.1002/hon.2693/v3/response1 ◽

2019 ◽

Author(s):

Irina V. Poddubnaya ◽

Sergey M. Alekseev ◽

Kamil D. Kaplanov ◽

Les M. Lukavetskyy ◽

Grigoriy B. Rekhtman ◽

...

Keyword(s):

Randomized Trial ◽

Author Response ◽

Decision letter for "Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: an international multicenter randomized trial"

10.1002/hon.2693/v2/decision1 ◽

2019 ◽

Keyword(s):

Randomized Trial ◽

An EORTC International Multicenter Randomized Trial (EORTC Number 19923) Comparing Two Dosages of Liposomal Amphotericin B for Treatment of Invasive Aspergillosis

Clinical Infectious Diseases ◽

10.1086/515033 ◽

1998 ◽

Vol 27 (6) ◽

pp. 1406-1412 ◽

Cited By ~ 191

Author(s):

M. Ellis ◽

D. Spence ◽

B. de Pauw ◽

F. Meunier ◽

A. Marinus ◽

...

Keyword(s):

Invasive Aspergillosis ◽

Randomized Trial ◽

Amphotericin B ◽

Liposomal Amphotericin ◽

Liposomal Amphotericin B ◽

Review for "Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: an international multicenter randomized trial"

10.1002/hon.2693/v1/review1 ◽

2019 ◽

Keyword(s):

Randomized Trial ◽